SCHEMBL3838713

SCHEMBL3838713

CCNc1cc(OC)ncc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.38
▸ NNMT P40261 1/20 0.36
▸ PGK1 P00558 4/20 0.35
▸ LOX P28300 1/20 0.35
▸ LOXL2 Q9Y4K0 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ PLEC Q15149 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ROCK1 Q13464 1/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ AOC1 P19801 2/20 0.33
▸ AOC3 Q16853 2/20 0.33
▸ SIRT6 Q8N6T7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24554040 0.80 EGFR (0.40) EGFRNNMTLOXLOXL2KDM4E
SCHEMBL15722546 0.75 KMT2A (0.47) PGK1KDM4EALDH1A1GAAMAPT
SCHEMBL3449998 0.75 KDM4E (0.37) PGK1KDM4EALDH1A1GAAMAPT
SCHEMBL18945474 0.74 MAPK1 (0.41) KDM4EALDH1A1GAAMAPTTHRB
SCHEMBL3449492 0.73 HCAR3 (0.46) PGK1ALDH1A1GAAMAPTHTT
SCHEMBL706595 0.73 NNMT (0.44) EGFRNNMTLOXLOXL2KDM4E
SCHEMBL29713548 0.73 NNMT (0.44) EGFRNNMTLOXLOXL2KDM4E
SCHEMBL24455820 0.73 NNMT (0.42) EGFRNNMTLOXLOXL2ROCK1
SCHEMBL21697451 0.72 EGFR (0.47) EGFRKDM4EALDH1A1GAAMAPT
SCHEMBL6295530 0.71 LMNA (0.47) LOXLOXL2KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 — — US disclosed
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 — — US disclosed
EP-2094670-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY AstraZeneca AB (SE) 2009-09-02 — — EP disclosed
WO-2008056150-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2008-05-15 — — WO disclosed
WO-2008056150-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY EDF1, ERLIN1, ECE1 EGFR 1607/4885NNMT 3453/4885PGK1 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback